Insights On Drug Discovery

  1. Here's Where CDMOs Improve For Cell And Gene Therapy Customers? 6/26/2025

    Donna Rill, Chief Technology Officer, Triumvira Immunologics, has advice for CDMOs to improve their service to CGT customers, and conversely, where drug developers can improve as well.

  2. Are You Asking For Unrealistic Flexibility At Your CDMO? 6/26/2025

    Our experienced Outsourced Pharma Live panel considers what is doable, and what is not, when it comes to the demands some sponsors put on CDMOs.

  3. Blood Brain Permeability And CNS Bioavailability Of Targeted Protein Degraders 6/20/2025

    Evidence suggests that the inherent flexibility of Targeted Protein Degraders (TPDs) can be leveraged to optimize key parameters such as solubility, permeability, and oral bioavailability.

  4. Experimental Pain Models — SNL Model Of Neuropathic Pain 6/20/2025

    Explore how a validated Spinal Nerve Ligation (SNL) model enables effective preclinical evaluation of novel analgesics for neuropathic pain.

  5. Elevating Purity: Racemizing Pharmaceutical Products In Flow Microreactors 6/18/2025

    Discover how our process development team resolved a racemization challenge by delivering a biologically active racemic mixture while maintaining compound purity.

  6. Experimental CCI — Induced Neuropathic Pain Model 6/18/2025

    Advance neuropathic pain research and therapeutic development with the Chronic Constriction Injury (CCI)-induced neuropathic pain model to uncover mechanisms and evaluate promising candidates.

  7. Column Head Loading In SFC: A Novel Injection Technique For Polar Heterocycles, Oligopeptides 6/13/2025

    By improving sample loading uniformity and reducing solubility-related artifacts, see how a multiple-injection approach enhances the practicality and effectiveness of SFC for difficult-to-purify substances.

  8. Leveraging Surface Plasmon Resonance For Characterizing Ternary Complexes 6/13/2025

    Uncover how Surface Plasmon Resonance (SPR) can be used to gain real-time, label-free insights into PROTAC binding kinetics and ternary complex formation.

  9. Preclinical Evaluation Of Vaccines And Antivirals In RSV Challenge Rodent Models 6/10/2025

    Here, we present multiple case studies utilizing clinically relevant mouse and rat models to evaluate key characteristics of potential RSV therapeutics.

  10. Preclinical Evaluation Of New Antifibrotics In NASH-Induced Fibrosis Models 6/10/2025

    Accelerate the development of antifibrotic therapies through our clinically relevant models, deep scientific expertise, and proven preclinical capabilities in this area of unmet medical need.